Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose
Phase 3
Completed
- Conditions
- Hepatitis A
- Registration Number
- NCT00483470
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Brief Summary
As per request by the Heath Authorities, the present clinical study will assess the immunogenicity and safety
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 720
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To provide information concerning the immunogenicity of AVAXIM 80U Pediatric vaccine 1 month post-vaccination
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of AVAXIM 80U's hepatitis A antigen in pediatric immune response?
How does AVAXIM 80U compare to other inactivated hepatitis A vaccines in terms of immunogenicity and adverse events?
What biomarkers correlate with antibody persistence after AVAXIM 80U primary series and booster dose?
What are the safety management strategies for hypersensitivity reactions to AVAXIM's aluminum hydroxide adjuvant?
How does Sanofi Pasteur's AVAXIM 80U regimen compare to GlaxoSmithKline's Havrix in pediatric hepatitis A prevention?